{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:55:16Z","timestamp":1763754916231,"version":"3.45.0"},"reference-count":29,"publisher":"Oncology Nursing Society (ONS)","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2009,12,1]]},"DOI":"10.1188\/09.cjon.s2.8-12","type":"journal-article","created":{"date-parts":[[2010,1,14]],"date-time":"2010-01-14T21:30:52Z","timestamp":1263504652000},"page":"8-12","source":"Crossref","is-referenced-by-count":1,"title":["Metastatic Renal Cell Carcinoma"],"prefix":"10.1188","volume":"13","author":[{"given":"John A.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2009,11,30]]},"reference":[{"issue":"1","key":"1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/mdi002","article-title":"Renal cell carcinoma: Review of novel single-agent therapeutics and combination regimens","volume":"16","author":"R. Amato","year":"2005","journal-title":"Annals of Oncology"},{"issue":"1","key":"2","first-page":"1","article-title":"Management of renal cell carcinoma and targeted therapy","volume":"3","author":"A. Canda","year":"2006","journal-title":"Urology Journal"},{"key":"3","unstructured":"Chiron Corp. (2007). <i>Proleukin<\/i>\u00ae [Prescribing information]. Emeryville, CA: Author."},{"issue":"55","key":"4","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal cell carcinoma","volume":"355","author":"H. Cohen","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ctrv.2005.07.009","article-title":"Renal cell carcinoma: Current status and future prospects","volume":"31","author":"B. Drucker","year":"2005","journal-title":"Cancer Treatment Reviews"},{"issue":"7","key":"6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.eursup.2007.01.017","article-title":"Adjuvant therapy in renal cell carcinoma: Where are we?","volume":"6","author":"T. Eisen","year":"2007","journal-title":"European Urology Supplements"},{"issue":"2","key":"7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear cell renal cell carcinoma","volume":"356","author":"B. Escudier","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"8","article-title":"A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab\/interferon-alfa 2a vs placebo\/interferon-alfa 2a as first-line therapy in metastatic renal cell carcinoma [Abstract 3]","volume":"25","author":"B. Escudier","year":"2007"},{"key":"9","unstructured":"Figlin, R.A., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., N\u00e9grier, X., et al. (2008). Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma [Abstract 5024]. Retrieved November 10, 2009, from <a target=\"_blank\" href='http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detailview&confID=55&abstractID=32895'>http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detailview&confID=55&abstractID=32895<\/a>"},{"issue":"23","key":"10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"R. Flanigan","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma","volume":"356","author":"G. Hudes","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"12","unstructured":"Klatte, T., de Martino, M., Shuch, B., LaRochelle, J., Kabbbinavar, F.F., Belldegrun, A.S., et al. (2008). Long-term outcome of interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma [Abstract 5119]. Retrieved November 10, 2009, from <a target=\"_blank\" href='http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detailview&confID=55&abstractID=30901'>http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detailview&confID=55&abstractID=30901<\/a>"},{"issue":"4","key":"13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ucl.2008.07.007","article-title":"Systemic therapy for metastatic renal cell carcinoma","volume":"35","author":"G. Kroog","year":"2008","journal-title":"Urologic Clinics of North America"},{"issue":"1","key":"14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"D. McDermott","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"9286","key":"15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial","volume":"358","author":"G. Mickisch","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1188\/08.ONF.699-708","article-title":"Renal cell carcinoma: The translation of molecular biology into new treatments, new patient outcomes, and nursing implications","volume":"35","author":"N. Moldawer","year":"2008","journal-title":"Oncology Nursing Forum"},{"issue":"9605","key":"17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(07)61874-1","article-title":"Targeted drugs for metastatic renal cell carcinoma","volume":"370","author":"R. Motzer","year":"2007","journal-title":"Lancet"},{"key":"18","unstructured":"National Cancer Institute. (2009). Dictionary of cancer terms: Glossary of statistical terms. Retrieved November 2, 2009, from <a target=\"_blank\" href='http:\/\/www.cancer.gov\/dictionary\/?CdrlD=618612'>http:\/\/www.cancer.gov\/dictionary\/?CdrlD=618612<\/a>"},{"key":"19","unstructured":"National Comprehensive Cancer Network. (2009). <i>NCCN Clinical Practice Guidelines in Oncology\u2122. Kidney cancer<\/i> [v.2.09]. Retrieved July 31, 2009, from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"key":"20","unstructured":"Novartis Pharmaceuticals. (2009). <i>Afinitor\u00ae<\/i> [Prescribing information]. East Hanover, New Jersey: Author."},{"key":"21","unstructured":"Onyx Pharmaceuticals. (2008). <i>Nexavar\u00ae<\/i> [Prescribing information]. Emeryville, CA: Author."},{"issue":"5","key":"22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0022-5347(05)65640-6","article-title":"The changing natural history of renal cell carcinoma","volume":"166","author":"A. Pantuck","year":"2001","journal-title":"Journal of Urology"},{"key":"23","unstructured":"Pfizer, Inc. (2008). <i>Sutent\u00ae<\/i> [prescribing information]. New York: Author."},{"issue":"6","key":"24","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.juro.2007.01.136","article-title":"The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy","volume":"177","author":"B. Rini","year":"2007","journal-title":"Journal of Urology"},{"issue":"33","key":"25","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"B. Rini","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CAD.0b013e3282f444de","article-title":"Metastatic renal cell carcinoma: Recent advances and current therapeutic options","volume":"19","author":"A. Schrader","year":"2008","journal-title":"Anti-cancer Drugs"},{"issue":"4","key":"27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1358\/dof.2007.032.04.1089088","article-title":"Ticilimumab","volume":"32","author":"Y. Wang","year":"2007","journal-title":"Drugs of the Future"},{"issue":"7","key":"28","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events","volume":"12","author":"J. Weber","year":"2007","journal-title":"Oncologist"},{"issue":"5","key":"29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1188\/07.CJON.649-656","article-title":"Sorafenib: A promising new targeted therapy for renal cell carcinoma","volume":"11","author":"L. Wood","year":"2007","journal-title":"Clinical Journal of Oncology Nursing"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/U711810787RXR42N.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:49:39Z","timestamp":1763754579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/13\/6\/supplement-december-2009-renal-cell-carcinoma\/metastatic-renal-cell"}},"subtitle":["Current Standards of Care"],"short-title":[],"issued":{"date-parts":[[2009,11,30]]},"references-count":29,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2009,12,1]]}},"alternative-id":["U711810787RXR42N"],"URL":"https:\/\/doi.org\/10.1188\/09.cjon.s2.8-12","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2009,11,30]]}}}